Clinical trialPhase 1Completed
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 29 December 2021
- Expected end
- 4 January 2024
- Enrollment
- 17 participants
- Sites
- 7
- Primary outcomes
- Dose limiting toxicity (DLT); Number of participants with adverse events and serious adverse events; Change in Vital Signs-ear temperature; Change in Vital Signs-pulse rate; Change in Vital Signs-systolic pressure
- Sponsor
- Industry
- Results posted
- No
- Last update
- 17 April 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
Detailed description public domain (ClinicalTrials.gov)
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors The study schedule includes screening visit (28 days prior to accept the investigational medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early withdrawal).